It was within this context that Glassman began ramping up his affiliation program. This was growth without a safety net: Anyone who passed his two-day seminar could apply to open a box, call it CrossFit, and then rush paying customers through squats and snatches or whatever crazy WOD they dreamed up. To Glassman, himself a passionate libertarian, this was the right thing to do: He wants his affiliates to be free to open up a box in a garage or a warehouse or wherever else, and train how they want, and charge what they want. They should have the opportunity he had. He detests supposed experts who say their certification or education makes them better than him or his people. At the end of the day, he believes, the free market will provide all the necessary quality control.
The WHO trial (so named because the international team of principal investigators contained World Health Organization members) tested the potential of clofibrate, a “pre-statin” cholesterol-lowering agent, to reduce heart attack morbidity and mortality. The investigators ultimately concluded that clofibrate "cannot be recommended as a lipid-lowering drug for community-wide primary prevention of ischaemic heart disease.” Nevertheless, clofibrate remained in use until 2002, when it was pulled for increasing cancer rates. In their review of studies such as the WHO trial, Uffe Ravnskov and David Diamond observe, “Despite the largely disappointing findings from 50 years of cholesterol lower[ing] trials, the indictment and conviction of cholesterol as the causal agent in CVD [cardiovascular disease] has stood the test of time. … [Yet] the grand effort to reduce cholesterol as a strategy to improve health has failed.”
×